Metraipolis › archive › dc_4559fe44babe

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and… — Europe PMC PMID:42827527

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42827527
DOI: 10.3389/fonc.2026.1884407
License (as archived): solo-consultazione
Archived: 2026-10-08T06:51:47.235Z
SHA-256 of the archived text: eab6b2d72c466617ab481d7452f5428702b64024c9265a5e29f20d8a9df57ee7
Stable URL of this page: https://metraipolis.com/documento/dc_4559fe44babe

How to cite

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and… — Europe PMC PMID:42827527 — Europe PMC (en), https://europepmc.org/article/MED/42827527 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4559fe44babe (Metraipolis archive dc_4559fe44babe, sha256 eab6b2d72c466617ab481d7452f5428702b64024c9265a5e29f20d8a9df57ee7)

BibTeX

@misc{dc4559fe44babe,
  title = {PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and… — Europe PMC PMID:42827527},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42827527},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4559fe44babe; sha256 eab6b2d72c466617ab481d7452f5428702b64024c9265a5e29f20d8a9df57ee7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42827527. Agents can read the archived copy with the MCP tool read_document.